Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Anti-PD-L1 (Durvalumab/MEDI4736) Plus Anti-CTLA-4 (Tremelimumab) and Radiation for High Risk Soft-Tissue Sarcoma

NCT03116529 is registered in ClinicalTrials.gov with University of Maryland, Baltimore as lead sponsor.

NCT NCT03116529
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03116529 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Anti-PD-L1 (Durvalumab/MEDI4736) Plus Anti-CTLA-4 (Tremelimumab) and Radiation for High Risk Soft-Tissue Sarcoma
Lead sponsor
University of Maryland, Baltimore
Phase
Phase 1/2
Overall status
Terminated
Start date
June 21, 2017
Completion date
June 21, 2024
Enrollment
22 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

soft tissue sarcoma